ECSP099736A - Aspartato de acido 1-ciclopropil-6-fluoro-7-(8-metoxiimino-2,6-diaza-espiro[3.4]oct-6-il)-4-oxo-1,4-dihidro-[1,8]naftiridin-3-carboxilico, metodo para preparar el mismo y composicion farmaceutica antimicrobiana que comprende el mismo - Google Patents

Aspartato de acido 1-ciclopropil-6-fluoro-7-(8-metoxiimino-2,6-diaza-espiro[3.4]oct-6-il)-4-oxo-1,4-dihidro-[1,8]naftiridin-3-carboxilico, metodo para preparar el mismo y composicion farmaceutica antimicrobiana que comprende el mismo

Info

Publication number
ECSP099736A
ECSP099736A EC2009009736A ECSP099736A ECSP099736A EC SP099736 A ECSP099736 A EC SP099736A EC 2009009736 A EC2009009736 A EC 2009009736A EC SP099736 A ECSP099736 A EC SP099736A EC SP099736 A ECSP099736 A EC SP099736A
Authority
EC
Ecuador
Prior art keywords
same
diaza
oxo
fluoro
oct
Prior art date
Application number
EC2009009736A
Other languages
English (en)
Inventor
Jei Man Ryu
Dong Rack Choi
Jin Yang
Sue Hye Yoon
Seung Hwan Kim
Sae Kwang Ku
Original Assignee
Dong Wha Pharm Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dong Wha Pharm Co Ltd filed Critical Dong Wha Pharm Co Ltd
Publication of ECSP099736A publication Critical patent/ECSP099736A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se describen sales de ácido aspártico de ácido 1-ciclopropil-6-fluoro-7-(8-metoxiimino-2,6-diaza-espiro[3.4]oct-6-il)-4-oxo-1,4-dihidro-[1,8]naftiridin-3-carboxílico, métodos para preparar las mismas, y composiciones farmacéuticas antimicrobianas que comprenden las mismas.
EC2009009736A 2007-04-13 2009-11-13 Aspartato de acido 1-ciclopropil-6-fluoro-7-(8-metoxiimino-2,6-diaza-espiro[3.4]oct-6-il)-4-oxo-1,4-dihidro-[1,8]naftiridin-3-carboxilico, metodo para preparar el mismo y composicion farmaceutica antimicrobiana que comprende el mismo ECSP099736A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR20070036574 2007-04-13

Publications (1)

Publication Number Publication Date
ECSP099736A true ECSP099736A (es) 2010-02-26

Family

ID=39864109

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2009009736A ECSP099736A (es) 2007-04-13 2009-11-13 Aspartato de acido 1-ciclopropil-6-fluoro-7-(8-metoxiimino-2,6-diaza-espiro[3.4]oct-6-il)-4-oxo-1,4-dihidro-[1,8]naftiridin-3-carboxilico, metodo para preparar el mismo y composicion farmaceutica antimicrobiana que comprende el mismo

Country Status (17)

Country Link
US (1) US8324238B2 (es)
EP (1) EP2134712B1 (es)
JP (1) JP5194105B2 (es)
KR (1) KR100953271B1 (es)
CN (1) CN101679416B (es)
AU (1) AU2008239966C1 (es)
BR (1) BRPI0810192C1 (es)
CA (1) CA2683939C (es)
CO (1) CO6251358A2 (es)
DK (1) DK2134712T3 (es)
EC (1) ECSP099736A (es)
ES (1) ES2436140T3 (es)
HK (1) HK1133881A1 (es)
MX (1) MX2009011063A (es)
PL (1) PL2134712T3 (es)
PT (1) PT2134712E (es)
WO (1) WO2008127060A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080109108A (ko) 2007-06-12 2008-12-17 (주)엘티엠에이피 휴대단말기용 스텝 힌지
KR101468659B1 (ko) * 2009-07-27 2014-12-05 주식회사 아리바이오 Ｒ-7-(3-아미노메틸-4-메톡시이미노-3-메틸-피롤리딘-1-일)-1-시클로프로필-6-플루오로-4-옥소-1,4-디히드로-[1,8]나프티리딘-3-카르복실산 ｌ-아스파르트산염, 이의 제조방법 및 이를 포함하는 항균용 약학적 조성물
KR101646324B1 (ko) * 2014-03-04 2016-08-05 동화약품주식회사 1-시클로프로필-6-플루오로-7-(8-메톡시이미노-2,6-디아자-스피로[3,4]옥트-6-일)-4-옥소-1,4-디히드로-[1,8]나프티리딘-3-카르복실산 디-아스파르트산염의 수화물 및 이를 포함하는 항균활성 조성물
CN103922987B (zh) * 2014-05-04 2016-09-28 苏州天马精细化学品股份有限公司 一种扎布沙星中间体及其合成方法
KR102213991B1 (ko) * 2014-05-20 2021-02-09 동화약품주식회사 개선된 자보플록사신의 제조방법
CN114894924B (zh) * 2022-04-21 2024-06-21 徐州医科大学 一种通过非衍生化gc-ms同时测定人血浆中4种抗癫痫药物的方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58966A (ja) * 1981-06-11 1983-01-06 ワ−ナ−−ランバ−ト・コンパニ− 抗菌性ナフチリジンおよびキノリン化合物の塩
ES512969A0 (es) 1981-06-11 1983-02-16 Warner Lambert Co "un procedimiento para preparar sales de compuestos de naftiridina y quinoleina".
DE3537761A1 (de) * 1985-10-24 1987-04-30 Bayer Ag Infusionsloesungen der 1-cyclopropyl-6-fluor-1,4-dihydro-4-oxo-7- (1-piperazinyl)-chinolin-3-carbonsaeure
KR960000223A (ko) * 1994-06-08 1996-01-25 김정순 신규한 피리돈 카르복실산 화합물을 함유한 수용액 및 이의 제조방법
JP3280388B2 (ja) * 1997-06-26 2002-05-13 ドング ホワ ファーマシューチカル インダストリアル カンパニー，リミテッド キノロンカルボン酸誘導体
EP1220678B1 (en) * 1999-10-04 2007-03-07 John Carter Pharmaceutical compositions containing copper, salicylic acid and vitamin c
ES2263960T3 (es) 2002-04-08 2006-12-16 Pfizer Inc. Derivados de tropano como moduladores de ccr5.

Also Published As

Publication number Publication date
JP5194105B2 (ja) 2013-05-08
PT2134712E (pt) 2013-11-26
AU2008239966C1 (en) 2012-03-29
EP2134712A4 (en) 2011-07-27
MX2009011063A (es) 2009-10-30
DK2134712T3 (da) 2013-11-18
HK1133881A1 (es) 2010-04-09
US8324238B2 (en) 2012-12-04
CN101679416A (zh) 2010-03-24
PL2134712T3 (pl) 2014-01-31
BRPI0810192A2 (pt) 2014-12-30
BRPI0810192C1 (pt) 2021-05-25
BRPI0810192B8 (pt) 2019-09-10
WO2008127060A1 (en) 2008-10-23
CO6251358A2 (es) 2011-02-21
CA2683939C (en) 2012-06-19
BRPI0810192B1 (pt) 2019-09-03
CA2683939A1 (en) 2008-10-23
KR100953271B1 (ko) 2010-04-16
CN101679416B (zh) 2012-06-27
EP2134712A1 (en) 2009-12-23
ES2436140T3 (es) 2013-12-27
JP2010523649A (ja) 2010-07-15
AU2008239966B2 (en) 2011-11-10
AU2008239966A1 (en) 2008-10-23
EP2134712B1 (en) 2013-08-21
US20100184795A1 (en) 2010-07-22
KR20080092893A (ko) 2008-10-16

Similar Documents

Publication Publication Date Title
PH12018502747A1 (en) Boronic acid derivatives and therapeutic uses thereof
EA033311B1 (ru) Производные бензоксаборола в качестве антибактериальных средств
CO6321253A2 (es) Formas cristalinas y dos formas solvatadas de sales de acido lactico de la 4- amino-5- fluoro-3-[5-(4-metil-piperazin-1-il)1h-bencimidazol-2-il]-quinolin-2(1h)-ona
UY31673A1 (es) "derivados heterocíclicos de urea y métodos de uso de los mismos-211"
BR112012029517A2 (pt) formulações de fragrância, métodos de fabricação e artigos compreendendo as mesmas.
TN2010000203A1 (en) Beta-lactamase inhibitors
ECSP099736A (es) Aspartato de acido 1-ciclopropil-6-fluoro-7-(8-metoxiimino-2,6-diaza-espiro[3.4]oct-6-il)-4-oxo-1,4-dihidro-[1,8]naftiridin-3-carboxilico, metodo para preparar el mismo y composicion farmaceutica antimicrobiana que comprende el mismo
MX355623B (es) Hidrazino-1h-imidazoquinolin-4-aminas y conjugados elaborados a partir de las mismas.
CL2013001464A1 (es) Compuestos derivados de imidazo[1,2-b]piridazina e imidazo[4,5-b]piridina, como inhibidores de jak; composicion farmaceutica que los comprende; producto de combinacion; y su uso en el tratamiento de enfermedades mieloproliferativas, leucemia, enfermedades mediadas por el sistema inmune y enfermedades inflamatorias, entre otras.
ECSP10010548A (es) Composiciones y metodos de preparacion y uso de las mismas
UY31860A (es) Piridinas de tiazolo como inhibidoras de la adn girasa
CR20130146A (es) Conjugado de naloxol-peg cristalino
IN2014DN07483A (es)
MX2016008128A (es) Intensificadores de aceptabilidad para alimento para mascotas, método de preparación y usos de los mismos.
CL2012002035A1 (es) Compuestos derivados de 1,2,6,7,8,9-hexahidrofuro[3,4-c]uinolina, inhibidores de cetp; procedimiento de preparacion de los compuestos principales intermediarios y de la composicion farmaceutica; composicion farmaceutica; sales farmaceuticas; utiles en el tratamiwento de tratornos cardipvasculares, tales como hipolipoproteinemia, dislipidemia, entre otras.
CL2009000510A1 (es) Compuestos derivados de 1,3,5,6,7,8-hexahidro-furo[3,4-b]quinolina, inhibidores de cetp; proceso de preparacion de los compuestos; composicion farmaceutica; proceso de preparacion de la composicion; y uso en el tratamiento y/o prevencion de trastornos cardiovasculares y trastornos relacionados.
MX2009000768A (es) Lactamas macrociclicas.
WO2014064652A3 (en) Stable pharmaceutical composition of peginterferon alpha-2b
GB0602951D0 (en) Organic Compounds
NO20082848L (no) Farmasoytisk formulering for behandling av osteoartritt inneholdende klodronsyre og hyaluronsyre
AU2013338098A8 (en) Solid salt form of alpha-6-mPEG6-O-hydroxycodone as opioid agonists and uses thereof
EP2611446A4 (en) CRYSTALLINE FORMS OF MARAVIROC PHOSPHATE AND PROCESS FOR THE PREPARATION OF THE AMORPHOUS FORM OF MARAVIROC
WO2013040535A3 (en) Bicarbocyclic and tricarbocyclic ethynyl derivatives and uses of same
WO2012022796A3 (de) Neue kombinationen
TH111755A (th) ไทรอะโซโลพิริดาซีนในรูปสารยับยั้ง par 1, การเตรียมของสารเหล่านั้นและการใช้สารเหล่านั้นเป็นยา